Can a plant-based vaccine treat hypertension?

Medical Hypotheses

Volumn 79, Issue 5, 2012, Pages 555-559

  Rosales Mendoza, Sergio ^a  

^a UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; VACCINE;

ANTIGEN EXPRESSION; ARTICLE; CLINICAL TRIAL (TOPIC); DRUG COST; DRUG FORMULATION; DRUG SAFETY; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL TRACT; HYPERTENSION; IMMUNOTHERAPY; NONHUMAN; PATIENT COMPLIANCE; PROTEIN PURIFICATION; VACCINATION;

HUMANS; HYPERTENSION; PLANTS; VACCINES;

EID: 84867337243     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2012.07.003     Document Type: Article

References (38)

1. Kearney P.M., Whelton M., Reynolds K., Whelton P.K., He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens 2004, 22:11-19.
2. Zhu F., Zhou Z., Liao Y. The renin-angiotensin system and therapeutic vaccines for hypertension. Curr Opin Invest Drugs 2008, 9:286-294.
3. Peach M.J. Renin-angiotensin system: biochemistry and mechanisms of action. Physiol Rev 1977, 57:313-370.
4. de Gasparo M., Catt K.J., Inagami T., Wright J.W., Unger T. International union of pharmacology XXIII. The angiotensin II receptors. Pharmacol Rev 2000, 52:415-472.
5. Senior K. Dosing in phase II trial of Alzheimer's vaccine suspended. Lancet Neurol 2002, 1:3.
6. Pandey R., Quan W.Y., Hong F., Jie S.L. Vaccine for hypertension: modulating the renin-angiotensin system. Int J Cardiol 2009, 134:160-168.
7. Michel J.B., Guettier C., Philippe M., Galen F.X., Corvol P., Menard J. Active immunization against renin in normotensive marmoset. Proc Natl Acad Sci USA 1987, 84:4346-4350.
8. Michel J.B., Sayah S., Guettier C., et al. Physiological and immunopathological consequences of active immunization of spontaneously hypertensive and normotensive rats against murine renin. Circulation 1990, 81:1899-1910.
9. Oates H.F., Stokes G.S., Storey B.G., Glover R.G., Snow B.F. Renal hypertension in rats immunized against angiotensin I and angiotensin II. J Exp Med 1974, 139:239-248.
10. Graham J.M., William J.L., Vincenzo R., Graham W.B., Stanley P. Renalclip hypertension in rabbits immunized against angiotensin II. Circ Res 1970, XXVII.
11. Johnston C.I., Hutchinson J.S., Mendelsohn F.A. Biological significance of renin-angiotensin immunization. Circ Res 1970, 27(Suppl. II):215.
12. Jennings G.T., Bachmann M.F. The coming of age of virus-like particle vaccines. Biol Chem 2008, 389:521-536.
13. Zhu F., Liao Y.H., Li L.D., Cheng M., Wei F., Wei Y.M., et al. Target organ protection from a novel angiotensin II receptor (AT1) vaccine ATR12181 in spontaneously hypertensive rats. Cell Mol Immunol 2006, 3:107-114.
14. Ambühl P.M., Tissot A.C., Fulurija A., Maurer P., Nussberger J., Sabat R., et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens 2007, 25:63-72.
15. Tissot A.C., Maurer P., Nussberger J., Sabat R., Pfister T., Ignatenko S., et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 2008, 371:821-827.
16. Mason H.S., Herbst-Kralovetz M.M. Plant-derived antigens as mucosal vaccines. Curr Top Microbiol Immunol 2012, 354:101-120.
17. Gleba Y., Klimyuk V., Marillonnet S. Magnifection-a new platform for expressing recombinant vaccines in plants. Vaccine 2005, 23:2042-2048.
18. Yusibov V., Streatfield S.J., Kushnir N. Clinical development of plant-produced recombinant pharmaceuticals: vaccines, antibodies, and beyond. Hum Vaccines 2011, 7:313-321.
19. Bosch D., Schots A. Plant glycans: friend or foe in vaccine development?. Expert Rev Vaccines 2010, 9:835-842.
20. Lawson L.B., Norton E.B., Clements J.D. Defending the mucosa: adjuvant and carrier formulations for mucosal immunity. Curr Opin Immunol 2011, 23:414-420.
21. Santi L., Huang Z., Mason H. Virus-like particles production in green plants. Methods 2006, 40:66-76.
22. Saldaña S. Esquivel Guadarrama F, Olivera Flores T de J, Arias N, López S, Arias C, Ruiz-Medrano R, Mason H, Mor T, Richter L, Arntzen CJ, Gómez Lim MA. Production of rotavirus-like particles in tomato (Lycopersicon esculentum L.) fruit by expression of capsid proteins VP2 and VP6 and immunological studies. Viral Immunol 2006, 19:42-53.
23. Huang Z., Santi L., LePore K., Kilbourne J., Arntzen C.J., Mason H.S. Rapid, high-level production of hepatitis B core antigen in plant leaf and its immunogenicity in mice. Vaccine 2006, 24:2506-2513.
24. Warzecha H., Mason H.S., Lane C., Tryggvesson A., Rybicki E., Williamson A.L., et al. Oral immunogenicity of human papillomavirus-like particles expressed in potato. J Virol 2003, 77:8702-8711.
25. Soria-Guerra R.E., Moreno-Fierros L., Rosales-Mendoza S. Two decades of plant-based candidate vaccines: a review of the chimeric protein approaches. Plant Cell Rep 2011, 30:1367-1382.
26. Granell A. Fernández del-Carmen A, Orzáez D. In planta production of plant-derived and non-plant-derived adjuvants. Expert Rev Vaccines 2010, 9:843-858.
27. Maliga P., Bock R. Plastid biotechnology: food, fuel, and medicine for the 21st century. Plant Physiol 2011, 155:1501-1510.
28. Gleba Y., Klimyuk V., Marillonnet S. Viral vectors for the expression of proteins in plants. Curr Opin Biotechnol 2007, 18:134-141.
29. Komarova T.V., Baschieri S., Donini M., Marusic C., Benvenuto E., Dorokhov Y.L. Transient expression systems for plant-derived biopharmaceuticals. Expert Rev Vaccines 2010, 9:859-876.
30. Kiprov D. Experimental models of hypertension. Cor Vasa 1980, 22:116-128.
31. Hallersund P., Elfvin A., Helander H.F., Fändriks L. The expression of renin-angiotensin system components in the human gastric mucosa. J Renin Angiotensin Aldosterone Syst 2010, 12:54-64.
32. Casselbrant A., Edebo A., Hallersund P., Spak E., Helander H.F., Jönson C., et al. Angiotensin II receptors are expressed and functional in human esophageal mucosa. Am J Physiol Gastrointest Liver Physiol 2009, 297:G1019-G1027.
33. Fändriks L. The renin-angiotensin system and the gastrointestinal mucosa. Acta Physiol (Oxf). 2011, 201:157-167.
34. Pavel J., Benicky J., Murakami Y., Sanchez-Lemus E., Saavedra J.M. Peripherally administered angiotensin II AT1 receptor antagonists are anti-stress compounds in vivo. Ann NY Acad Sci 2008, 1148:360-366.
35. Brown M.J., Coltart J., Gunewardena K., Ritter J.M., Auton T.R., Glover J.F. Randomized double-blind placebo-controlled study of an angiotensin immunotherapeutic vaccine (PMD3117) in hypertensive subjects. Clin Sci (Lond) 2004, 107(2):167-173.
36. Rosales-Mendoza S., Alpuche-Solís A.G., Soria-Guerra R.E., Moreno-Fierros L., Martínez-González L., Herrera-Díaz A., et al. Expression of an Escherichia coli antigenic fusion protein comprising the heat labile toxin B subunit and the heat stable toxin, and its assembly as a functional oligomer in transplastomic tobacco plants. Plant J 2009, 57:45-54.
37. Daniell H., Lee S.B., Panchal T., Wiebe P.O. Expression of the native cholera toxin B subunit gene and assembly as functional oligomers in transgenic tobacco chloroplasts. J Mol Biol 2001, 311:1001-1009.
38. Guan Z.J., Guo B., Huo Y.L., Guan Z.P., Wei Y.H. Overview of expression of hepatitis B surface antigen in transgenic plants. Vaccine 2010, 28:7351-7362.